0001104659-20-015176.txt : 20200210
0001104659-20-015176.hdr.sgml : 20200210
20200210203000
ACCESSION NUMBER: 0001104659-20-015176
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200206
FILED AS OF DATE: 20200210
DATE AS OF CHANGE: 20200210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gelone Steven P.
CENTRAL INDEX KEY: 0001693064
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 20593563
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics plc
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: (610) 816-6640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Therapeutics AG
DATE OF NAME CHANGE: 20150507
4
1
a4.xml
4
X0306
4
2020-02-06
0
0001641640
Nabriva Therapeutics plc
NBRV
0001693064
Gelone Steven P.
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA
PA
19406
0
1
0
0
President & COO
Ordinary Shares
2020-02-06
4
A
0
155000
0
A
326919
D
Stock Options
1.35
2020-02-06
4
A
0
310000
0
A
2030-02-05
Ordinary Shares
310000
310000
D
The reported transaction involved the reporting person's receipt of a grant of 155,000 restricted stock units. The total reported in Column 5 includes the 155,000 newly awarded restricted stock units.
The option was granted on February 6, 2020, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right.
The option will vest over a four-year period beginning on February 6, 2020. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period.
/s/ Robert Crotty, by power of attorney
2020-02-10